ATTACHMENT A

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

1. (Currently amended) A therapeutical method comprising administration of a composition comprising a monoclonal antibody with ~~either a β-(1,3)-glucan like laminarin or~~ an oligo-β-(1,3)-glucan and a pharmaceutically acceptable carrier, to a human being or to a warm-blood animal suffering from cancer in an amount which is effective to treat the cancer.

2. (Currently amended) The method according to claim 1, wherein the oligo-β-(1,3)-glucan is a compound presenting the following formula (1):



in which n=1 to 10, ~~preferably, n=2 or 3,~~
or a pharmaceutical acceptable salt thereof.

3. (Original) The method according to claim 2, wherein the monoclonal antibody is any monoclonal antibody specific to molecular determinants present on cancer cells and simultaneously able to activate complement.

4. (Original) The method according to claim 1, wherein the cancer is leukemia, adenocarcinoma, breast cancer, lung cancer, ovarian cancer, oesophagus cancer, gastric cancer, intestinal cancer, non-Hodgkin lymphoma or colon cancer.

5. (Currently amended) The method according to claim 1, wherein the monoclonal antibody and ~~either a β-(1,3)-glucan like laminarin or~~ an oligo-β-(1,3)-glucan are administered simultaneously, sequentially or successively.

6. (Currently amended) The method according to claim 1, wherein the composition for use in a successive, sequential or simultaneous treatment can be administered intravenously or intraperitoneally to the patient, under the form of injections, ointment, pulmonary spray; and the composition for use in a sequential treatment can also be administered in the following way: the monoclonal antibody is administered intravenously while the ~~β-(1,3)-glucan like Laminarin or~~ oligo- β-(1,3)-glucan is administered orally to the patient, under the form of a solution, suspension, syrup, tablet, capsule.

7. (Currently amended) The method according to claim 1, wherein the effective amount of ~~either β-(1,3)-glucan like Laminarin or~~ oligo- β-(1,3)-glucan is 2 to 20mg/kg when administered orally.

8. (Currently amended) Pharmaceutical composition under the form of an injection, ointment, pulmonary spray comprising a therapeutically effective amount of a monoclonal antibody and ~~either β-(1,3)-glucan like Laminarin or~~ an oligo-β-(1,3)-glucan of formula (1)



in which n=1 to 10, ~~preferably n=2 or n=3~~,
or a salt pharmaceutically acceptable salt thereof,
and a pharmaceutical acceptable carrier,
said composition being free of any other glucan.

9. (Currently amended) Pharmaceutical composition according to claim ~~9~~8, further comprising a chemotherapeutic agent.

10. (New) The method according to claim 1, wherein the oligo-β-(1,3)-glucan is a compound presenting the following formula (1):



in which n=2 or 3,

or a pharmaceutical acceptable salt thereof.

11. (New) Pharmaceutical composition under the form of an injection, ointment, pulmonary spray comprising a therapeutically effective amount of a monoclonal antibody and an oligo-β-(1,3)-glucan of formula (1)



in which n=2 or n=3,

or a salt pharmaceutically acceptable salt thereof,

and a pharmaceutical acceptable carrier,

said composition being free of any other glucan.